The Retinoid X Receptor Agonist, 9-cis UAB30, Inhibits Cutaneous T-cell Lymphoma Proliferation Through the SKP2-p27kip1 Axis

Cutaneous T-cell lymphomas (CTCLs) are characterized by the localization of neoplastic T lymphocytes in the skin. The most common forms of CTCLs are mycosis fungoides (MF) and Sézary syndrome (SS), which account for 65% of CTCLs [1]. The clinical features of MF are erythematous patches, plaques, and, in severe cases, pruritus and tumor formation [2]. SS is an advanced form of CTCL that includes skin lesions with neoplastic CD4+ T lymphocytes in the blood. In the United States, there are ∼1500 new cases reported each year, and the incidence is increasing [3,4].